Screener
Summit Therapeutics SMMT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
FAQ
- What is Summit Therapeutics's cash & equivalents?
- Summit Therapeutics (SMMT) reported cash & equivalents of $8.24M in Q1 2026.
- How has Summit Therapeutics's cash & equivalents changed year-over-year?
- Summit Therapeutics's cash & equivalents increased by 7.2% year-over-year, from $7.68M to $8.24M.
- What is the long-term trend for Summit Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Summit Therapeutics's cash & equivalents has grown at a -24.4% compound annual growth rate (CAGR), from $66.42M to $16.37M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Summit Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude